Overview

ESPRIT Study in Hypogonadal Men

Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
Observational study with AndroGel®, Testosterone 1% gel therapy (ESPRIT) in hypogonadal men in the community over 6 months.
Details
Lead Sponsor:
Abbott
Collaborator:
Fovea
Treatments:
Methyltestosterone
Testosterone
Testosterone 17 beta-cypionate
Testosterone enanthate
Testosterone undecanoate